ovarian cancer

A new method traces treatment resistant cells and predicts drugs that can make them more susceptible to cancer therapy.

Rounds of trial-and-error exploring the layer of cells covering the ovary leave open questions about stem cells that are associated with ovarian cancer.

A pair of new studies finds that analyzing material from a Pap smear can reveal tumor risk in distant parts of the body, potentially allowing early interventions.

Knowingly facing the end of her life, she raised hundreds of thousands of dollars for underrepresented students in higher education.

Over nearly 50 years, the Monell Chemical Senses Center chemist investigated a range of topics, from the smell of cancer to body odor’s effects on human physiology and behavior.

The Creighton University researcher discovered the genetic basis of hereditary breast-ovarian cancer syndrome.

The test can pick up several types of cancer, including pancreatic and ovarian, years before symptoms appear.

A preliminary clinical trial finds that the personalized therapy improves survival rates and has no severe side-effects.

In the largest study of its kind to date, researchers find more than 850 rare, heritable genetic alterations that can predispose humans to cancer.

With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.

The University of Minnesota researcher is on the front lines in the fight against the disease.

Researchers were able to slow tumor growth in a mouse model of human ovarian cancer. 

The new diagnostic works by identifying cancer-associated proteins and DNA in patient blood.

Family members of Lacks, the donor behind the widely used HeLa cell line, are planning to sue Johns Hopkins University.

A jury recently awarded $72 million in a talcum-powder–ovarian cancer case, but the data linking the hygiene product to disease risk are inconclusive.

Color Genomics announces a new, lower-cost BRCA mutation test, while Inserm and Quest Diagnostics reveal plans to pool patient data to investigate rare mutations.

In a large study, researchers find evidence to suggest that the type and location of a woman’s BRCA1/2 mutations may affect her cancer risk.

Researchers report an ability to detect several types of cancer in blood samples based on signatures of immune response, but some are skeptical about the utility of such a test.